LevetIracetam in Patients Being Treated for Epilepsy

Study Overview
=================
Brief Summary
-----------------
Epilepsy is one of the most common neurological diseases.Approximately 53 million people suffering from chronic recurrent epilepsy in 1990 and that number increased about 58 million in 2005. The annual incidence of epilepsy varies considerably in different epidemiological studies, ranging from 11 cases per 100,000 general population to 230 cases per 100,000 people. To date there has been discovered the ideal Antiepileptic Drugs. The drug, ie, that are safe and effective, it has good daily administration frequency, easily administered from all roads, which has high bioavailability, which is not highly bound to proteins, and not holding inductive or inhibitory effect.

Detailed Description
-----------------
There are broad-spectrum anticonvulsant, which means that a drug can be very effective for a patient, but may or may not regulate and increase the frequency of another crisis. Thus there remains now only to choose one among a number of drugs, the most appropriate.This study intends to register within 12 months clinical practice in Greek reality as regards the elements of diagnosis and management of patients with epilepsy and those who already are, or are part of treatment with levetiracetam. The aims of this clinical study is to record data on the diagnosis The management of epilepsy in daily clinical practice in a sample of Greek population The monitoring of patients entering or already undergoing treatment with levetiracetam. The assessment of quality of life between visits of the study by using quality of life QOLIE-31 questionnaire The economic evaluation of the change in treatment from original to generic levetiracetam This is a data recording study and evaluation of treatment with levetiracetam. The study will take place in 15 antiepileptic centers throughout Greece. Researchers will have to successively record all incidents of patients (30 per center) with epilepsy, which are new diagnoses or already diagnosed and are treated with levetiracetam.

Official Title
-----------------
The Diagnosis and Management of Patients With Epilepsy: Nationwide, Multicenter Study of Recordings for the Diagnosis and Management of Patients With Epilepsy and Treatment With Levetiracetam in Daily Clinical Practice in Greece

Conditions
-----------------
Epilepsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients Males and Females Age> 6 years Patients diagnosed with epilepsy or Patients who are diagnosed and treated with antiepileptic treatment levetiracetam Patients who consent to their participation in the study Patients will comply with the requirements and procedures of the study Exclusion Criteria: Patients who did not consent to their participation in the study Patients who will not comply to the needs and the design process

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in seizures' status (Change of number of seizures from baseline) | Change of number of seizures from baseline | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in adverse events | Change of number of adverse events from baseline | 12 months | 
| Change in treatment cost | Change in treatment cost from baseline | 12 months | 
| Change in Quality of Life | Change in QoLie score from baseline | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
seizures,, quality of life